Rising Pharma recalls 25mg/100mg/200mg Carbidopa Levodopa Entacapone tablets (NDC 16571-691-01) because some bottles contain higher strength tablets (37.5mg/150mg/200mg) instead of the labeled strength.
Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).
Rising Pharma is recalling 100-count bottles of Carbidopa, Levodopa, and Entacapone tablets (25mg/100mg/200mg) because some bottles were mistakenly labeled with higher strength tablets (37.5mg/150mg/200mg). This mix-up could lead to incorrect dosing and potential health risks for patients using these medications.
The medication bottles were mistakenly filled with higher strength tablets (37.5mg/150mg/200mg) instead of the labeled lower strength (25mg/100mg/200mg). This mix-up could result in patients receiving a higher dose than intended, potentially causing adverse effects.
Patients prescribed Carbidopa, Levodopa, and Entacapone tablets for Parkinson's disease who received the recalled 100-count bottles. Those with higher strength tablets may be at risk of incorrect dosing.
Check for the NDC code 16571-691-01 and lot number CS25070 on the bottle. The product was manufactured for Rising Pharma Holdings, Inc. in East Brunswick, NJ, and shipped from Suven Pharmaceuticals in India.
Verify the tablet strength on the label: 25mg/100mg/200mg for the recalled product or 37.5mg/150mg/200mg for the incorrect strength.
The recall is due to a product mix-up where some bottles contained higher strength tablets (37.5mg/150mg/200mg) instead of the labeled lower strength (25mg/100mg/200mg).
The official recall notice does not specify a remedy or action for affected patients. Check the label to confirm the tablet strength and contact your healthcare provider if you have concerns.
The recall notice does not indicate a risk of serious injury; the hazard is a potential dosing error due to incorrect tablet strength.
We’ve drafted a message you can send Rising Pharma to request your refund or repair — edit it as you like.
Subject: Recall D-0029-2026 — Rising Pharma Rising Pharma Hello, I own a Rising Pharma that is covered by recall D-0029-2026 from Rising Pharma. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
